These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 10616177)
1. Molecular consistency monitoring of oral poliovirus vaccine and other live viral vaccines. Chumakov KM Dev Biol Stand; 1999; 100():67-74. PubMed ID: 10616177 [No Abstract] [Full Text] [Related]
2. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Macadam AJ; Pollard SR; Ferguson G; Skuce R; Wood D; Almond JW; Minor PD Virology; 1993 Jan; 192(1):18-26. PubMed ID: 8390752 [TBL] [Abstract][Full Text] [Related]
3. New assays for the quality control of live oral poliovirus vaccine. Furesz J; Levenbook I Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944 [TBL] [Abstract][Full Text] [Related]
4. The potential use of viral genomic markers in estimating the neurovirulence of oral poliomyelitis vaccine (OPV): regulatory aspects. Fenyves A Dev Biol Stand; 1993; 78():157-9. PubMed ID: 8388826 [No Abstract] [Full Text] [Related]
5. On the role of the World Health Organization in the development of Sabin vaccines. Magrath D; Reeve P Biologicals; 1993 Dec; 21(4):345-8. PubMed ID: 8024749 [TBL] [Abstract][Full Text] [Related]
7. Use of animals in the development and control of viral vaccines. Minor PD Dev Biol Stand; 1996; 86():113-20. PubMed ID: 8785940 [TBL] [Abstract][Full Text] [Related]
8. Monitoring vaccines for human oncogenicity. Miller RW Natl Cancer Inst Monogr; 1968 Dec; 29():453-5. PubMed ID: 4305436 [No Abstract] [Full Text] [Related]
9. Evaluation of the new control methods for oral poliomyelitis vaccine. Grachev VP; Karganova GG; Rumyantsev AA; Ivanova OE; Eremeeva TP; Drozdov SG Dev Biol (Basel); 2001; 105():211-7. PubMed ID: 11763330 [TBL] [Abstract][Full Text] [Related]
10. Determinants of monovalent oral polio vaccine mutagenesis in vaccinated elderly people. Boot HJ; Sonsma J; van Nunen F; Abbink F; Kimman TG; Buisman AM Vaccine; 2007 Jun; 25(24):4706-14. PubMed ID: 17482726 [TBL] [Abstract][Full Text] [Related]
11. Clinical experience with vaccines produced in the human diploid cell line WI-38. Andzaparidze OG Natl Cancer Inst Monogr; 1968 Dec; 29():477-84. PubMed ID: 4976367 [No Abstract] [Full Text] [Related]
12. An historical outline of the development of live poliovaccine and its non-target effects. Horaud F Dev Biol Stand; 1995; 84():117-22. PubMed ID: 7796943 [No Abstract] [Full Text] [Related]
13. Polio endgame. Polio: The final assault? Roberts L Science; 2004 Mar; 303(5666):1960-8. PubMed ID: 15044779 [No Abstract] [Full Text] [Related]
14. Laboratory tests for live attenuated poliovirus vaccines. Wood DJ; Macadam AJ Biologicals; 1997 Mar; 25(1):3-15. PubMed ID: 9167004 [TBL] [Abstract][Full Text] [Related]
15. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus. Friedrich F Acta Virol; 2000 Apr; 44(2):109-17. PubMed ID: 10989702 [TBL] [Abstract][Full Text] [Related]
16. Analysis of mutations in oral poliovirus vaccine by hybridization with generic oligonucleotide microchips. Proudnikov D; Kirillov E; Chumakov K; Donlon J; Rezapkin G; Mirzabekov A Biologicals; 2000 Jun; 28(2):57-66. PubMed ID: 10885613 [TBL] [Abstract][Full Text] [Related]
17. Polio's last stand. Clarke T Nature; 2001 Jan; 409(6818):278-80. PubMed ID: 11201713 [No Abstract] [Full Text] [Related]
18. Inactivated vaccines based on alternatives to wild-type seed virus. Chumakov K; Dragunsky E; Ivshina A; Enterline J; Wells V; Nomura T; Gromeier M; Wimmer E Dev Biol (Basel); 2001; 105():171-7. PubMed ID: 11763325 [No Abstract] [Full Text] [Related]